SDI’s Tara Harding honored by Healthcare Businesswomen’s Association
NEW YORK — Tara Harding, SDI senior director of sales operations, was honored as an industry rising star by the Healthcare Businesswomen’s Association during its 2011 Woman of the Year award luncheon Thursday.
“Tara exemplifies the ideal of a selfless, team-oriented professional,” stated Andrew Kress, SDI’s CEO. “She is an innovative problem solver who has had a consistently positive impact on all areas of SDI, from sales to finance to customer operations. She leads by tireless example, and with her guidance, her team redesigned, implemented and monitored an entirely new system of sales metrics that significantly improved SDI’s sales results and customer service.”
HBA is a global not-for-profit organization dedicated to furthering the advancement of women in healthcare worldwide. HBA Rising Stars are professionals in various sectors of the healthcare industry, including pharmaceutical, biotechnology, advertising, public relations, medical education and market research, among other fields, who represent various career stages and disciplines. The nomination demonstrates recognition by Rising Stars’ companies and colleagues of the outstanding performance, commitment to excellence, and energy and enthusiasm with which they approach activities daily to contribute to their companies’ success.
Harding has been with SDI since 2002, when she began in the finance department. She now oversees SDI’s sales operations, contract administration and forecasting.
FlavoRx, RDC ink deal
COLUMBIA, Md. — FlavoRx and Rochester Drug Cooperative on Thursday announced a long-term distribution agreement designed to bring the FlavoRx brand to more than 950 independent pharmacies serviced by RDC throughout New York, New Jersey, Pennsylvania, Ohio and Connecticut.
At the same time, RDC expects the FlavoRx product line, including the new Fillmaster Plus, to provide its customers with unique offerings that add to the value it already brings to independent pharmacies in the region.
“We are delighted to partner with RDC to better serve the needs of independent pharmacies in the region,” stated Natasha Hobson, FlavoRx director of accounts. “The team at RDC has a deep understanding of the independent pharmacy market and truly cares about the continued success of [its] customers. Adding FlavoRx and Fillmaster to [its] portfolio is a progressive step that will give [its] customers access to unique products designed to enhance workflow and customer service while improving patient outcomes.”
As part of the partnership, RDC representatives now will offer the new Fillmaster Plus, a pharmacy device that automates drug reconstitution.
OTC industry homogenizes concentration of APAP liquids for kids
WASHINGTON — The Consumer Healthcare Products Association on Wednesday announced plans to convert liquid pediatric acetaminophen products to just one concentration.
This voluntary change means the current children’s strength of liquid acetaminophen (160 mg/5 mL) will become the only liquid concentration available for all children younger than 12 years, and the current concentrated infant drops no longer will be sold.
“CHPA member companies are voluntarily making this conversion to one concentration to help make it easier for parents and caregivers to appropriately use single-ingredient liquid acetaminophen,” stated CHPA president and CEO Scott Melville. “We are committed to providing parents and caregivers with the tools and information they need to help give their children the right amount of these medicines.“
CHPA and its members will be working to ensure healthcare providers have the information they need to help answer parents’ questions about the change. During the transition, the makers of these medicines also will work with retailers to ensure that, as the new medicines are introduced, the more concentrated infant drops will be removed from store shelves.
The single-concentration liquid medicines will have additional enhancements to their age-appropriate dosing devices. Specifically, infants’ products will have syringes for more accurate dosing and flow restrictors. Children’s products, for kids ages 2 years to younger than 12 years, will continue to offer dosing cups.
APAP is the most commonly used children’s medicine for relieving pain and reducing fever, according to the CHPA. The transition will begin in mid-2011.